Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

103.83 +0.08 (+0.08%)
Streaming Delayed Price Updated: 9:43 AM EDT, Mar 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Exact Sciences Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
1 Magnificent Dividend Stock Down 22% That's a Screaming Buy Right Now ↗
Don't give up on this leading dividend payer yet. 
Via The Motley Fool
News headline image
1 Mid-Cap Stock to Consider Right Now and 2 Facing Headwinds
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man... 
Via StockStory
News headline image
Hedge Fund Beryl Capital Initiated a Position in CSG Systems Worth Over $54 Million. Is the Stock a Buy? ↗
CSG Systems International delivers SaaS-based billing and customer engagement solutions to telecom and enterprise clients worldwide. 
Via The Motley Fool
EXACT SCIENCES CORP (NASDAQ:EXAS) Shows Strong Technical and Fundamental Momentum ↗
Via Chartmill
News headline image
Macroeconomic Headwinds and Shifting Demand Force Healthcare Giants to Trim 2026 Outlooks
As the first quarter of 2026 draws to a close, the healthcare and life sciences sectors are grappling with a "new normal" defined by capital conservatism and geopolitical friction. Industry... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
3 Cash-Producing Stocks We Approach with Caution
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
The Return of the Titans: M&A Volume Set to Surge 20% in 2026 Amidst "Animal Spirits"
As of March 4, 2026, the global financial landscape is witnessing a seismic shift in corporate strategy. After years of cautious maneuvering and high interest rates, the "animal spirits" of the... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time ↗
Abbott Laboratories is delivering double-digit percentage earnings growth along with a dependable dividend. 
Via The Motley Fool
Topics Cannabis Initial Public Offering
News headline image
Medtronic Hits 10-Quarter High: PFA Dominance and Robotic Surges Signal a New Era for MedTech
In a definitive sign that the medical technology sector has moved past its post-pandemic stagnation, Medtronic (NYSE: MDT) reported its strongest enterprise revenue growth in ten quarters for the third... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
Boston Scientific’s $14.5B Penumbra Mega-Merger: A Strategic Reshaping of the Medtech Landscape
On January 15, 2026, the medical technology sector witnessed its most significant seismic shift in years as Boston Scientific Corporation (NYSE:BSX) announced a definitive agreement to acquire... 
Via MarketMinute
News headline image
3 Unpopular Stocks We Approach with Caution
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can... 
Via StockStory
Topics Economy
News headline image
3 Overrated Stocks That Concern Us
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions. 
Via StockStory
News headline image
Abbott Labs: The Healthcare Dividend Stock I'd Happily Hold Forever ↗
Abbott is the name behind many well-known products. 
Via The Motley Fool
News headline image
1 Momentum Stock with Exciting Potential and 2 Facing Headwinds
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial... 
Via StockStory
News headline image
Exact Sciences (EXAS): Buy, Sell, or Hold Post Q3 Earnings?
What a time it’s been for Exact Sciences. In the past six months alone, the company’s stock price has increased by a massive 152%, reaching $103.18 per share. This was partly due to its solid quarterly... 
Via StockStory
News headline image
The Era of the Titans: Q4 2025 Mega-Deal Surge and the 2026 Economic Map
As of February 6, 2026, the global financial landscape is still reverberating from a historic tectonic shift that occurred in the final months of last year. In the fourth quarter of 2025, the M&A... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
1 Growth Stock to Stash and 2 We Avoid
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
Topics Climate Change
News headline image
The Best Dividend King to Buy With $150 ↗
The stock is near its 52-week low. 
Via The Motley Fool
News headline image
Boston Scientific’s $14.5 Billion Stroke of Genius: Consolidation Heats Up in the Medtech Arms Race
In a move that has sent shockwaves through the healthcare sector, Boston Scientific (NYSE:BSX) has announced a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
3 Reasons to Buy This Dividend King After Its Steep Sell-Off ↗
Investors' reaction to this Dividend King's Q4 revenue miss was overdone. 
Via The Motley Fool
Topics Earnings
News headline image
Abbott Laboratories Shares Plunge 10% Following Q4 Revenue Miss and Diagnostics Weakness
Abbott Laboratories (NYSE: ABT) saw its stock price tumble by nearly 10% in early trading on January 22, 2026, following the release of its fourth-quarter 2025 financial results. Despite meeting... 
Via MarketMinute
Topics Economy
News headline image
Abbott Shares Slump as Revenue Miss and Exact Sciences Acquisition Jitters Overshadow Earnings Beat
Abbott Laboratories (NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an... 
Via MarketMinute
Topics Earnings Economy
News headline image
$5.1 Trillion Global Surge: CEO Confidence Ignites New Era of M&A Transformation
The global Mergers and Acquisitions (M&A) market staged a historic comeback in 2025, with total deal value reaching a staggering $5.1 trillion. This resurgence represents a 44% year-over-year increase,... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
The Great Diagnostic Consolidation: How a $25.7 Billion Mega-Deal Ignited a 150% Surge in Healthcare M&A
As 2026 begins, the healthcare sector is undergoing its most profound transformation in decades. Driven by a relentless push toward "precision medicine" and the industrialization of artificial... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth
In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an... 
Via MarketMinute
News headline image
Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization
Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that... 
Via MarketMinute
News headline image
Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability
On January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025... 
Via MarketMinute
Topics Artificial Intelligence Death
News headline image
3 Mid-Cap Stocks We Steer Clear Of
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
1 High-Flying Stock on Our Watchlist and 2 We Question
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.